// App-Quantinova.ai

LBA505 : Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

Researchers

Presenter

  • Halle C. F. Moore

Principal Investigators

  • Kelly-Anne Phillips

  • Carlos Vallejos

  • Ann H. Partridge

  • Shaker R. Dakhil

  • Silvana Martino

  • William E. Barlow

  • Carol J. Fabian

  • Frank L. Meyskens

  • Gabriel N. Hortobagyi

  • David James Porter

  • Prudence A. Francis

  • Lori M. Minasian

  • Richard D. Gelber

  • Lori J. Goldstein

  • Henry Leonidas Gomez

  • Kathy S. Albain

  • Frances M. Boyle

  • Erika Hitre

Medical Centers

  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • National Institute of Oncology, Budapest, Hungary

  • Dana-Farber Cancer Institute, Boston, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • National Cancer Institute, Bethesda, MD

  • Department of Oncology, Auckland City Hospital, Auckland, New Zealand

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Loyola University Medical Center, Maywood, IL

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • SWOG Statistical Center, Seattle, WA

  • Cancer Research and Biostats, Seattle, WA

  • University of Kansas Medical Center, Kansas City, MO

  • The Angeles Clinic and Research Institute, Santa Monica, CAInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru

  • Cleveland Clinic, Cleveland, OH

  • Oncosalud - Auna, Lima, Peru

  • Wichita Community Clinical Oncology Program, Wichita, KS

  • The Mater Hospital, Sydney, Australia

  • UCI Comprehensive Cancer Center, Orange, CA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Australia

  • United States

  • Peru

  • New Zealand

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Premature ovarian failure

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Progesterone receptor

  • Follicle-stimulating hormone

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Goserelin

  • LHRH

Outcome

  • Positive

Study Design

  • randomized

Phase

  • III

Study Id's

  • NCT00068601

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved